FLX475, an investigational anti-cancer therapy by RAPT Therapeutics, is safe and shows promising anti-tumor clinical activity, both alone and in combination with Keytruda (pembrolizumab), in certain types of cancer. These are the preliminary findings of a global, open-label Phase 1/2 trial (NCT03674567), which is recruiting participants across 32 sites in the U.S., Australia, and Asia. “We are pleased with the early evidence of clinical activity of FLX475, both as monotherapy and in combination with pembrolizumab…
You must be logged in to read/download the full post.
The post FLX475 Shows Promising Safety, Anti-Tumor Activity; Trial Recruiting appeared first on BioNewsFeeds.